Medtronic (NYSE:MDT) last week challenged a pair of Masimo (NSDQ:MASI) patents covering pulse oximetry technology, filing inter partes reviews with the U.S. Patent & Trademark Office.
The petitions allege that claims in 1 of the patents, covering “Signal processing apparatus,” are obvious due to prior art that the patent office “did not fully consider during prosecution as the prior art did not form the basis of a rejection.” Medtronic alleges obviousness and anticipation for the 2nd patent, according to documents filed with the PTO’s Patent Trial & Appeal Board.
Help employers find you! Check out all the jobs and post your resume.
